Global Anti-obesity Drugs Market By Drug Type (Prescription Drugs, OTC Drugs), By Mechanism of Action (Centrally Acting Drugs, Peripherally Acting Drugs, Gut-Hormone Incretins- GLP-1 Agonists, Dual Agonists/GIP Agonists), By Route of Administration (Oral, Injectable), By Patient Type (Adults, Pediatrics), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), Region and Companies – Industry Segment Outlook, Market Assessment, Competition Scenario, Trends and Forecast 2025-2034

Table of Contents

• 1. Executive Summary
  • 1.1. Definition
  • 1.2. Market Snapshot
  • 1.3. Market Overview
  • 1.4. Segment Overview
  • 1.5. Regional Overview
  • 1.6. Competitive Landscape
  • 1.7. Taxonomy
  • 1.8. Industry Voices
• 2. Global Market Overview
  • 2.1. Global Market Insights and Industry Overview
  • 2.2. Market Dynamics
    • 2.2.1. Drivers
    • 2.2.2. Restraints
    • 2.2.3. Opportunities
    • 2.2.4. Key Anti-obesity Drugs Market Trends
  • 2.3. Mechanism of Action Landscape
  • 2.4. Regulatory Framework
  • 2.5. Sustainability and ESG (Environmental, Social, Governance)
  • 2.6. Opportunity Map Analysis
  • 2.7. Opportunity Orbits
  • 2.8. PESTLE Analysis
  • 2.9. PORTER’S Five Force Analysis
  • 2.10. Drivers & Restraints Impact Analysis
  • 2.11. Value Chain Analysis
    • 2.11.1. List of Raw Materials Suppliers
    • 2.11.2. List of Anti-obesity Drugs Manufacturers
    • 2.11.3. List of Dealer/Distributors
  • 2.12. Regional Market Share and BPS Analysis
  • 2.13. Impact of Macro-economic Factors/Geopolitical Factors
• 3. Global Anti-obesity Drugs Market Analysis and Forecast, By Segment, 2020-2034
  • 3.1. Key Findings
  • 3.2. Global Anti-obesity Drugs Market Size Value (US$ Mn) Analysis, Opportunity and Forecast, By Drug Type, 2020-2034
  • 3.3. Global Anti-obesity Drugs Market Attractiveness Analysis, By Drug Type
    • 3.3.1. Prescription Drugs
      • 3.3.1.1. Insights
      • 3.3.1.2. Key Takeaways
    • 3.3.2. OTC Drugs
      • 3.3.2.1. Insights
      • 3.3.2.2. Key Takeaways
  • 3.4. Global Anti-obesity Drugs Market Size Value (US$ Mn) Analysis, Opportunity and Forecast, By Mechanism of Action, 2020-2034
  • 3.5. Global Anti-obesity Drugs Market Attractiveness Analysis, By Mechanism of Action
    • 3.5.1. Centrally Acting Drugs
      • 3.5.1.1. Insights
      • 3.5.1.2. Key Takeaways
    • 3.5.2. Peripherally Acting Drugs
      • 3.5.2.1. Insights
      • 3.5.2.2. Key Takeaways
    • 3.5.3. Gut-Hormone Incretins
      • 3.5.3.1. Insights
      • 3.5.3.2. Key Takeaways
      • 3.5.3.3. GLP-1 Agonists
      • 3.5.3.4. Dual Agonists/GIP Agonists
  • 3.6. Global Anti-obesity Drugs Market Size Value (US$ Mn) Analysis, Opportunity and Forecast, By Route of Administration, 2020-2034
  • 3.7. Global Anti-obesity Drugs Market Attractiveness Analysis, By Route of Administration
    • 3.7.1. Oral
      • 3.7.1.1. Insights
      • 3.7.1.2. Key Takeaways
    • 3.7.2. Injectable
      • 3.7.2.1. Insights
      • 3.7.2.2. Key Takeaways
  • 3.8. Global Anti-obesity Drugs Market Size Value (US$ Mn) Analysis, Opportunity and Forecast, By Patient Type, 2020-2034
  • 3.9. Global Anti-obesity Drugs Market Attractiveness Analysis, By Patient Type
    • 3.9.1. Adults
      • 3.9.1.1. Insights
      • 3.9.1.2. Key Takeaways
    • 3.9.2. Pediatrics
      • 3.9.2.1. Insights
      • 3.9.2.2. Key Takeaways
  • 3.10. Global Anti-obesity Drugs Market Size Value (US$ Mn) Analysis, Opportunity and Forecast, By Distribution Channel, 2020-2034
  • 3.11. Global Anti-obesity Drugs Market Attractiveness Analysis, By Distribution Channel
    • 3.11.1. Hospital Pharmacies
      • 3.11.1.1. Insights
      • 3.11.1.2. Key Takeaways
    • 3.11.2. Retail Pharmacies
      • 3.11.2.1. Insights
      • 3.11.2.2. Key Takeaways
    • 3.11.3. Online Pharmacies
      • 3.11.3.1. Insights
      • 3.11.3.2. Key Takeaways
• 4. Global Anti-obesity Drugs Market Analysis and Forecast, By Region, 2020-2034
  • 4.1. Key Findings
  • 4.2. Global Anti-obesity Drugs Market Size Value (US$ Mn) Analysis, Opportunity and Forecast, By Region, 2020-2034
    • 4.2.1. North America
      • 4.2.1.1. Regional Insights
    • 4.2.2. Europe
      • 4.2.2.1. Regional Insights
    • 4.2.3. Asia Pacific
      • 4.2.3.1. Regional Insights
    • 4.2.4. Latin America
      • 4.2.4.1. Regional Insights
    • 4.2.5. Middle East & Africa
      • 4.2.5.1. Regional Insights
  • 4.3. Global Anti-obesity Drugs Market Attractiveness Analysis, By Region
• 5. North America Anti-obesity Drugs Market Analysis and Forecast, 2020-2034
  • 5.1. Key Findings
  • 5.2. North America Anti-obesity Drugs Market Size Value (US$ Mn) Analysis, Opportunity and Forecast, By Drug Type, 2020-2034
  • 5.3. North America Anti-obesity Drugs Market Attractiveness Analysis, By Drug Type
  • 5.4. North America Anti-obesity Drugs Market Size Value (US$ Mn) Analysis, Opportunity and Forecast, By Mechanism of Action, 2020-2034
  • 5.5. North America Anti-obesity Drugs Market Attractiveness Analysis, By Mechanism of Action
  • 5.6. North America Anti-obesity Drugs Market Size Value (US$ Mn) Analysis, Opportunity and Forecast, By Route of Administration, 2020-2034
  • 5.7. North America Anti-obesity Drugs Market Attractiveness Analysis, By Route of Administration
  • 5.8. North America Anti-obesity Drugs Market Size Value (US$ Mn) Analysis, Opportunity and Forecast, By Patient Type, 2020-2034
  • 5.9. North America Anti-obesity Drugs Market Attractiveness Analysis, By Patient Type
  • 5.10. North America Anti-obesity Drugs Market Size Value (US$ Mn) Analysis, Opportunity and Forecast, By Distribution Channel, 2020-2034
  • 5.11. North America Anti-obesity Drugs Market Attractiveness Analysis, By Distribution Channel
  • 5.12. North America Anti-obesity Drugs Market Size Value (US$ Mn) Analysis, Opportunity and Forecast, By Country, 2020-2034
  • 5.13. North America Anti-obesity Drugs Market Attractiveness Analysis, By Country
    • 5.13.1. The US
    • 5.13.2. Canada
• 6. Europe Anti-obesity Drugs Market Analysis and Forecast, 2020-2034
  • 6.1. Key Findings
  • 6.2. Europe Anti-obesity Drugs Market Size Value (US$ Mn) Analysis, Opportunity and Forecast, By Drug Type, 2020-2034
  • 6.3. Europe Anti-obesity Drugs Market Attractiveness Analysis, By Drug Type
  • 6.4. Europe Anti-obesity Drugs Market Size Value (US$ Mn) Analysis, Opportunity and Forecast, By Mechanism of Action, 2020-2034
  • 6.5. Europe Anti-obesity Drugs Market Attractiveness Analysis, By Mechanism of Action
  • 6.6. Europe Anti-obesity Drugs Market Size Value (US$ Mn) Analysis, Opportunity and Forecast, By Route of Administration, 2020-2034
  • 6.7. Europe Anti-obesity Drugs Market Attractiveness Analysis, By Route of Administration
  • 6.8. Europe Anti-obesity Drugs Market Size Value (US$ Mn) Analysis, Opportunity and Forecast, By Patient Type, 2020-2034
  • 6.9. Europe Anti-obesity Drugs Market Attractiveness Analysis, By Patient Type
  • 6.10. Europe Anti-obesity Drugs Market Size Value (US$ Mn) Analysis, Opportunity and Forecast, By Distribution Channel, 2020-2034
  • 6.11. Europe Anti-obesity Drugs Market Attractiveness Analysis, By Distribution Channel
  • 6.12. Europe Anti-obesity Drugs Market Size Value (US$ Mn) Analysis, Opportunity and Forecast, By Country, 2020-2034
  • 6.13. Europe Anti-obesity Drugs Market Attractiveness Analysis, By Country
    • 6.13.1. Germany
    • 6.13.2. The UK
    • 6.13.3. France
    • 6.13.4. Spain
    • 6.13.5. Italy
    • 6.13.6. Russia
    • 6.13.7. Netherland
    • 6.13.8. Rest of Europe
• 7. Asia Pacific Anti-obesity Drugs Market Analysis and Forecast, 2020-2034
  • 7.1. Key Findings
  • 7.2. Asia Pacific Anti-obesity Drugs Market Size Value (US$ Mn) Analysis, Opportunity and Forecast, By Drug Type, 2020-2034
  • 7.3. Asia Pacific Anti-obesity Drugs Market Attractiveness Analysis, By Drug Type
  • 7.4. Asia Pacific Anti-obesity Drugs Market Size Value (US$ Mn) Analysis, Opportunity and Forecast, By Mechanism of Action, 2020-2034
  • 7.5. Asia Pacific Anti-obesity Drugs Market Attractiveness Analysis, By Mechanism of Action
  • 7.6. Asia Pacific Anti-obesity Drugs Market Size Value (US$ Mn) Analysis, Opportunity and Forecast, By Route of Administration, 2020-2034
  • 7.7. Asia Pacific Anti-obesity Drugs Market Attractiveness Analysis, By Route of Administration
  • 7.8. Asia Pacific Anti-obesity Drugs Market Size Value (US$ Mn) Analysis, Opportunity and Forecast, By Patient Type, 2020-2034
  • 7.9. Asia Pacific Anti-obesity Drugs Market Attractiveness Analysis, By Patient Type
  • 7.10. Asia Pacific Anti-obesity Drugs Market Size Value (US$ Mn) Analysis, Opportunity and Forecast, By Distribution Channel, 2020-2034
  • 7.11. Asia Pacific Anti-obesity Drugs Market Attractiveness Analysis, By Distribution Channel
  • 7.12. Asia Pacific Anti-obesity Drugs Market Size Value (US$ Mn) Analysis, Opportunity and Forecast, By Country, 2020-2034
  • 7.13. Asia Pacific Anti-obesity Drugs Market Attractiveness Analysis, By Country
    • 7.13.1. China
    • 7.13.2. Japan
    • 7.13.3. South Korea
    • 7.13.4. India
    • 7.13.5. Australia
    • 7.13.6. New Zealand
    • 7.13.7. Singapore
    • 7.13.8. Thailand
    • 7.13.9. Vietnam
    • 7.13.10. Rest of Asia Pacific
• 8. Latin America Anti-obesity Drugs Market Analysis and Forecast, 2020-2034
  • 8.1. Key Findings
  • 8.2. Latin America Anti-obesity Drugs Market Size Value (US$ Mn) Analysis, Opportunity and Forecast, By Drug Type, 2020-2034
  • 8.3. Latin America Anti-obesity Drugs Market Attractiveness Analysis, By Drug Type
  • 8.4. Latin America Anti-obesity Drugs Market Size Value (US$ Mn) Analysis, Opportunity and Forecast, By Mechanism of Action, 2020-2034
  • 8.5. Latin America Anti-obesity Drugs Market Attractiveness Analysis, By Mechanism of Action
  • 8.6. Latin America Anti-obesity Drugs Market Size Value (US$ Mn) Analysis, Opportunity and Forecast, By Route of Administration, 2020-2034
  • 8.7. Latin America Anti-obesity Drugs Market Attractiveness Analysis, By Route of Administration
  • 8.8. Latin America Anti-obesity Drugs Market Size Value (US$ Mn) Analysis, Opportunity and Forecast, By Patient Type, 2020-2034
  • 8.9. Latin America Anti-obesity Drugs Market Attractiveness Analysis, By Patient Type
  • 8.10. Latin America Anti-obesity Drugs Market Size Value (US$ Mn) Analysis, Opportunity and Forecast, By Distribution Channel, 2020-2034
  • 8.11. Latin America Anti-obesity Drugs Market Attractiveness Analysis, By Distribution Channel
  • 8.12. Latin America Anti-obesity Drugs Market Size Value (US$ Mn) Analysis, Opportunity and Forecast, By Country, 2020-2034
  • 8.13. Latin America Anti-obesity Drugs Market Attractiveness Analysis, By Country
    • 8.13.1. Brazil
    • 8.13.2. Mexico
    • 8.13.3. Rest of Latin America
• 9. Middle East & Africa Anti-obesity Drugs Market Analysis and Forecast, 2020-2034
  • 9.1. Key Findings
  • 9.2. Middle East & Africa Anti-obesity Drugs Market Size Value (US$ Mn) Analysis, Opportunity and Forecast, By Drug Type, 2020-2034
  • 9.3. Middle East & Africa Anti-obesity Drugs Market Attractiveness Analysis, By Drug Type
  • 9.4. Middle East & Africa Anti-obesity Drugs Market Size Value (US$ Mn) Analysis, Opportunity and Forecast, By Mechanism of Action, 2020-2034
  • 9.5. Middle East & Africa Anti-obesity Drugs Market Attractiveness Analysis, By Mechanism of Action
  • 9.6. Middle East & Africa Anti-obesity Drugs Market Size Value (US$ Mn) Analysis, Opportunity and Forecast, By Route of Administration, 2020-2034
  • 9.7. Middle East & Africa Anti-obesity Drugs Market Attractiveness Analysis, By Route of Administration
  • 9.8. Middle East & Africa Anti-obesity Drugs Market Size Value (US$ Mn) Analysis, Opportunity and Forecast, By Patient Type, 2020-2034
  • 9.9. Middle East & Africa Anti-obesity Drugs Market Attractiveness Analysis, By Patient Type
  • 9.10. Middle East & Africa Anti-obesity Drugs Market Size Value (US$ Mn) Analysis, Opportunity and Forecast, By Distribution Channel, 2020-2034
  • 9.11. Middle East & Africa Anti-obesity Drugs Market Attractiveness Analysis, By Distribution Channel
  • 9.12. Middle East & Africa Anti-obesity Drugs Market Size Value (US$ Mn) Analysis, Opportunity and Forecast, By Country, 2020-2034
  • 9.13. Middle East & Africa Anti-obesity Drugs Market Attractiveness Analysis, By Country
    • 9.13.1. South Africa
    • 9.13.2. Saudi Arabia
    • 9.13.3. UAE
    • 9.13.4. Rest of Middle East & Africa
• 10. Competitive Landscape & Company Profiles
  • 10.1. Market Competition Scenario Analysis, By Company
    • 10.1.1. Key Takeaways
  • 10.2. Overview of Major Market Players
  • 10.3. Competitor Landscape
  • 10.4. Strategic Mapping
  • 10.5. Company Life Cycle Analysis
  • 10.6. Company Market Share Analysis
  • 10.7. Company Profiles
    • 10.7.1. Novo Nordisk A/S
      • 10.7.1.1. Company Details
      • 10.7.1.2. Business Overview
      • 10.7.1.3. Product Portfolio
      • 10.7.1.4. Financial Insights
      • 10.7.1.5. Key Developments (Investments & Expansions, Merger & Acquisition, Partnership & Agreement and New Product Development)
      • 10.7.1.6. SWOT Analysis
      • 10.7.1.7. Geographic Footprint
    • 10.7.2. Eli Lilly and Company
      • 10.7.2.1. Company Details
      • 10.7.2.2. Business Overview
      • 10.7.2.3. Product Portfolio
      • 10.7.2.4. Financial Insights
      • 10.7.2.5. Key Developments (Investments & Expansions, Merger & Acquisition, Partnership & Agreement and New Product Development)
      • 10.7.2.6. SWOT Analysis
      • 10.7.2.7. Geographic Footprint
    • 10.7.3. F. Hoffmann-La Roche AG
      • 10.7.3.1. Company Details
      • 10.7.3.2. Business Overview
      • 10.7.3.3. Product Portfolio
      • 10.7.3.4. Financial Insights
      • 10.7.3.5. Key Developments (Investments & Expansions, Merger & Acquisition, Partnership & Agreement and New Product Development)
      • 10.7.3.6. SWOT Analysis
      • 10.7.3.7. Geographic Footprint
    • 10.7.4. Pfizer Inc.
      • 10.7.4.1. Company Details
      • 10.7.4.2. Business Overview
      • 10.7.4.3. Product Portfolio
      • 10.7.4.4. Financial Insights
      • 10.7.4.5. Key Developments (Investments & Expansions, Merger & Acquisition, Partnership & Agreement and New Product Development)
      • 10.7.4.6. SWOT Analysis
      • 10.7.4.7. Geographic Footprint
    • 10.7.5. GSK plc
      • 10.7.5.1. Company Details
      • 10.7.5.2. Business Overview
      • 10.7.5.3. Product Portfolio
      • 10.7.5.4. Financial Insights
      • 10.7.5.5. Key Developments (Investments & Expansions, Merger & Acquisition, Partnership & Agreement and New Product Development)
      • 10.7.5.6. SWOT Analysis
      • 10.7.5.7. Geographic Footprint
    • 10.7.6. Currax Pharmaceuticals LLC
      • 10.7.6.1. Company Details
      • 10.7.6.2. Business Overview
      • 10.7.6.3. Product Portfolio
      • 10.7.6.4. Financial Insights
      • 10.7.6.5. Key Developments (Investments & Expansions, Merger & Acquisition, Partnership & Agreement and New Product Development)
      • 10.7.6.6. SWOT Analysis
      • 10.7.6.7. Geographic Footprint
    • 10.7.7. Boehringer Ingelheim International GmbH
      • 10.7.7.1. Company Details
      • 10.7.7.2. Business Overview
      • 10.7.7.3. Product Portfolio
      • 10.7.7.4. Financial Insights
      • 10.7.7.5. Key Developments (Investments & Expansions, Merger & Acquisition, Partnership & Agreement and New Product Development)
      • 10.7.7.6. SWOT Analysis
      • 10.7.7.7. Geographic Footprint
    • 10.7.8. Amgen Inc.
      • 10.7.8.1. Company Details
      • 10.7.8.2. Business Overview
      • 10.7.8.3. Product Portfolio
      • 10.7.8.4. Financial Insights
      • 10.7.8.5. Key Developments (Investments & Expansions, Merger & Acquisition, Partnership & Agreement and New Product Development)
      • 10.7.8.6. SWOT Analysis
      • 10.7.8.7. Geographic Footprint
    • 10.7.9. AstraZeneca plc
      • 10.7.9.1. Company Details
      • 10.7.9.2. Business Overview
      • 10.7.9.3. Product Portfolio
      • 10.7.9.4. Financial Insights
      • 10.7.9.5. Key Developments (Investments & Expansions, Merger & Acquisition, Partnership & Agreement and New Product Development)
      • 10.7.9.6. SWOT Analysis
      • 10.7.9.7. Geographic Footprint
    • 10.7.10. Merck & Co., Inc.
      • 10.7.10.1. Company Details
      • 10.7.10.2. Business Overview
      • 10.7.10.3. Product Portfolio
      • 10.7.10.4. Financial Insights
      • 10.7.10.5. Key Developments (Investments & Expansions, Merger & Acquisition, Partnership & Agreement and New Product Development)
      • 10.7.10.6. SWOT Analysis
      • 10.7.10.7. Geographic Footprint
    • 10.7.11. Zealand Pharma
      • 10.7.11.1. Company Details
      • 10.7.11.2. Business Overview
      • 10.7.11.3. Product Portfolio
      • 10.7.11.4. Financial Insights
      • 10.7.11.5. Key Developments (Investments & Expansions, Merger & Acquisition, Partnership & Agreement and New Product Development)
      • 10.7.11.6. SWOT Analysis
      • 10.7.11.7. Geographic Footprint
    • 10.7.12. Takeda Pharmaceutical Co. Ltd
      • 10.7.12.1. Company Details
      • 10.7.12.2. Business Overview
      • 10.7.12.3. Product Portfolio
      • 10.7.12.4. Financial Insights
      • 10.7.12.5. Key Developments (Investments & Expansions, Merger & Acquisition, Partnership & Agreement and New Product Development)
      • 10.7.12.6. SWOT Analysis
      • 10.7.12.7. Geographic Footprint
    • 10.7.13. Rhythm Pharmaceuticals, Inc.
      • 10.7.13.1. Company Details
      • 10.7.13.2. Business Overview
      • 10.7.13.3. Product Portfolio
      • 10.7.13.4. Financial Insights
      • 10.7.13.5. Key Developments (Investments & Expansions, Merger & Acquisition, Partnership & Agreement and New Product Development)
      • 10.7.13.6. SWOT Analysis
      • 10.7.13.7. Geographic Footprint
    • 10.7.14. Vivus LLC
      • 10.7.14.1. Company Details
      • 10.7.14.2. Business Overview
      • 10.7.14.3. Product Portfolio
      • 10.7.14.4. Financial Insights
      • 10.7.14.5. Key Developments (Investments & Expansions, Merger & Acquisition, Partnership & Agreement and New Product Development)
      • 10.7.14.6. SWOT Analysis
      • 10.7.14.7. Geographic Footprint
    • 10.7.15. Zydus Lifesciences Ltd.
      • 10.7.15.1. Company Details
      • 10.7.15.2. Business Overview
      • 10.7.15.3. Product Portfolio
      • 10.7.15.4. Financial Insights
      • 10.7.15.5. Key Developments (Investments & Expansions, Merger & Acquisition, Partnership & Agreement and New Product Development)
      • 10.7.15.6. SWOT Analysis
      • 10.7.15.7. Geographic Footprint
    • 10.7.16. Gelesis Holdings Inc.
      • 10.7.16.1. Company Details
      • 10.7.16.2. Business Overview
      • 10.7.16.3. Product Portfolio
      • 10.7.16.4. Financial Insights
      • 10.7.16.5. Key Developments (Investments & Expansions, Merger & Acquisition, Partnership & Agreement and New Product Development)
      • 10.7.16.6. SWOT Analysis
      • 10.7.16.7. Geographic Footprint
    • 10.7.17. Teva Pharmaceuticals Company Limited
      • 10.7.17.1. Company Details
      • 10.7.17.2. Business Overview
      • 10.7.17.3. Product Portfolio
      • 10.7.17.4. Financial Insights
      • 10.7.17.5. Key Developments (Investments & Expansions, Merger & Acquisition, Partnership & Agreement and New Product Development)
      • 10.7.17.6. SWOT Analysis
      • 10.7.17.7. Geographic Footprint
    • 10.7.18. Hanmi Pharm.Co.,Ltd
      • 10.7.18.1. Company Details
      • 10.7.18.2. Business Overview
      • 10.7.18.3. Product Portfolio
      • 10.7.18.4. Financial Insights
      • 10.7.18.5. Key Developments (Investments & Expansions, Merger & Acquisition, Partnership & Agreement and New Product Development)
      • 10.7.18.6. SWOT Analysis
      • 10.7.18.7. Geographic Footprint
    • 10.7.19. Verdiva
      • 10.7.19.1. Company Details
      • 10.7.19.2. Business Overview
      • 10.7.19.3. Product Portfolio
      • 10.7.19.4. Financial Insights
      • 10.7.19.5. Key Developments (Investments & Expansions, Merger & Acquisition, Partnership & Agreement and New Product Development)
      • 10.7.19.6. SWOT Analysis
      • 10.7.19.7. Geographic Footprint
    • 10.7.20. HK inno.N Corp.
      • 10.7.20.1. Company Details
      • 10.7.20.2. Business Overview
      • 10.7.20.3. Product Portfolio
      • 10.7.20.4. Financial Insights
      • 10.7.20.5. Key Developments (Investments & Expansions, Merger & Acquisition, Partnership & Agreement and New Product Development)
      • 10.7.20.6. SWOT Analysis
      • 10.7.20.7. Geographic Footprint
    • 10.7.21. Dr. Reddy’s Laboratories
      • 10.7.21.1. Company Details
      • 10.7.21.2. Business Overview
      • 10.7.21.3. Product Portfolio
      • 10.7.21.4. Financial Insights
      • 10.7.21.5. Key Developments (Investments & Expansions, Merger & Acquisition, Partnership & Agreement and New Product Development)
      • 10.7.21.6. SWOT Analysis
      • 10.7.21.7. Geographic Footprint
• 11. Methodology and Data Source
  • 11.1. Methodology/Research Approach
  • 11.2. Market Size Estimation
  • 11.3. Market Breakdown and Data Triangulation
  • 11.4. Data Source
  • 11.5. Secondary Sources
  • 11.6. Primary Sources
  • 11.7. Appendix
  • 11.8. Disclaimer

List of Tables

• Table 1. Global Anti-obesity Drugs Market Value (US$ Mn), By Drug Type, 2020-2034
• Table 2. Global Anti-obesity Drugs Market Value (US$ Mn), By Mechanism of Action, 2020-2034
• Table 3. Global Anti-obesity Drugs Market Value (US$ Mn), By Gut-Hormone Incretins, 2020-2034
• Table 4. Global Anti-obesity Drugs Market Value (US$ Mn), By Route of Administration, 2020-2034
• Table 5. Global Anti-obesity Drugs Market Value (US$ Mn), By Patient Type, 2020-2034
• Table 6. Global Anti-obesity Drugs Market Value (US$ Mn), By Distribution Channel, 2020-2034
• Table 7. Global Anti-obesity Drugs Market Value (US$ Mn), By Region, 2020-2034
• Table 8. North America Anti-obesity Drugs Market Value (US$ Mn), By Drug Type, 2020-2034
• Table 9. North America Anti-obesity Drugs Market Value (US$ Mn), By Mechanism of Action, 2020-2034
• Table 10. North America Anti-obesity Drugs Market Value (US$ Mn), By Gut-Hormone Incretins, 2020-2034
• Table 11. North America Anti-obesity Drugs Market Value (US$ Mn), By Route of Administration, 2020-2034
• Table 12. North America Anti-obesity Drugs Market Value (US$ Mn), By Patient Type, 2020-2034
• Table 13. North America Anti-obesity Drugs Market Value (US$ Mn), By Distribution Channel, 2020-2034
• Table 14. North America Anti-obesity Drugs Market Value (US$ Mn), By Country, 2020-2034
• Table 15. The US Anti-obesity Drugs Market Value (US$ Mn), By Drug Type, 2020-2034
• Table 16. The US Anti-obesity Drugs Market Value (US$ Mn), By Mechanism of Action, 2020-2034
• Table 17. The US Anti-obesity Drugs Market Value (US$ Mn), By Gut-Hormone Incretins, 2020-2034
• Table 18. The US Anti-obesity Drugs Market Value (US$ Mn), By Route of Administration, 2020-2034
• Table 19. The US Anti-obesity Drugs Market Value (US$ Mn), By Patient Type, 2020-2034
• Table 20. The US Anti-obesity Drugs Market Value (US$ Mn), By Distribution Channel, 2020-2034
• Table 21. Canada Anti-obesity Drugs Market Value (US$ Mn), By Drug Type, 2020-2034
• Table 22. Canada Anti-obesity Drugs Market Value (US$ Mn), By Mechanism of Action, 2020-2034
• Table 23. Canada Anti-obesity Drugs Market Value (US$ Mn), By Gut-Hormone Incretins, 2020-2034
• Table 24. Canada Anti-obesity Drugs Market Value (US$ Mn), By Route of Administration, 2020-2034
• Table 25. Canada Anti-obesity Drugs Market Value (US$ Mn), By Patient Type, 2020-2034
• Table 26. Canada Anti-obesity Drugs Market Value (US$ Mn), By Distribution Channel, 2020-2034
• Table 27. Europe Anti-obesity Drugs Market Value (US$ Mn), By Drug Type, 2020-2034
• Table 28. Europe Anti-obesity Drugs Market Value (US$ Mn), By Mechanism of Action, 2020-2034
• Table 29. Europe Anti-obesity Drugs Market Value (US$ Mn), By Gut-Hormone Incretins, 2020-2034
• Table 30. Europe Anti-obesity Drugs Market Value (US$ Mn), By Route of Administration, 2020-2034
• Table 31. Europe Anti-obesity Drugs Market Value (US$ Mn), By Patient Type, 2020-2034
• Table 32. Europe Anti-obesity Drugs Market Value (US$ Mn), By Distribution Channel, 2020-2034
• Table 33. Europe Anti-obesity Drugs Market Value (US$ Mn), By Country, 2020-2034
• Table 34. Germany Anti-obesity Drugs Market Value (US$ Mn), By Drug Type, 2020-2034
• Table 35. Germany Anti-obesity Drugs Market Value (US$ Mn), By Mechanism of Action, 2020-2034
• Table 36. Germany Anti-obesity Drugs Market Value (US$ Mn), By Gut-Hormone Incretins, 2020-2034
• Table 37. Germany Anti-obesity Drugs Market Value (US$ Mn), By Route of Administration, 2020-2034
• Table 38. Germany Anti-obesity Drugs Market Value (US$ Mn), By Patient Type, 2020-2034
• Table 39. Germany Anti-obesity Drugs Market Value (US$ Mn), By Distribution Channel, 2020-2034
• Table 40. The UK Anti-obesity Drugs Market Value (US$ Mn), By Drug Type, 2020-2034
• Table 41. The UK Anti-obesity Drugs Market Value (US$ Mn), By Mechanism of Action, 2020-2034
• Table 42. The UK Anti-obesity Drugs Market Value (US$ Mn), By Gut-Hormone Incretins, 2020-2034
• Table 43. The UK Anti-obesity Drugs Market Value (US$ Mn), By Route of Administration, 2020-2034
• Table 44. The UK Anti-obesity Drugs Market Value (US$ Mn), By Patient Type, 2020-2034
• Table 45. The UK Anti-obesity Drugs Market Value (US$ Mn), By Distribution Channel, 2020-2034
• Table 46. France Anti-obesity Drugs Market Value (US$ Mn), By Drug Type, 2020-2034
• Table 47. France Anti-obesity Drugs Market Value (US$ Mn), By Mechanism of Action, 2020-2034
• Table 48. France Anti-obesity Drugs Market Value (US$ Mn), By Gut-Hormone Incretins, 2020-2034
• Table 49. France Anti-obesity Drugs Market Value (US$ Mn), By Route of Administration, 2020-2034
• Table 50. France Anti-obesity Drugs Market Value (US$ Mn), By Patient Type, 2020-2034
• Table 51. France Anti-obesity Drugs Market Value (US$ Mn), By Distribution Channel, 2020-2034
• Table 52. Spain Anti-obesity Drugs Market Value (US$ Mn), By Drug Type, 2020-2034
• Table 53. Spain Anti-obesity Drugs Market Value (US$ Mn), By Mechanism of Action, 2020-2034
• Table 54. Spain Anti-obesity Drugs Market Value (US$ Mn), By Gut-Hormone Incretins, 2020-2034
• Table 55. Spain Anti-obesity Drugs Market Value (US$ Mn), By Route of Administration, 2020-2034
• Table 56. Spain Anti-obesity Drugs Market Value (US$ Mn), By Patient Type, 2020-2034
• Table 57. Spain Anti-obesity Drugs Market Value (US$ Mn), By Distribution Channel, 2020-2034
• Table 58. Italy Anti-obesity Drugs Market Value (US$ Mn), By Drug Type, 2020-2034
• Table 59. Italy Anti-obesity Drugs Market Value (US$ Mn), By Mechanism of Action, 2020-2034
• Table 60. Italy Anti-obesity Drugs Market Value (US$ Mn), By Gut-Hormone Incretins, 2020-2034
• Table 61. Italy Anti-obesity Drugs Market Value (US$ Mn), By Route of Administration, 2020-2034
• Table 62. Italy Anti-obesity Drugs Market Value (US$ Mn), By Patient Type, 2020-2034
• Table 63. Italy Anti-obesity Drugs Market Value (US$ Mn), By Distribution Channel, 2020-2034
• Table 64. Russia Anti-obesity Drugs Market Value (US$ Mn), By Drug Type, 2020-2034
• Table 65. Russia Anti-obesity Drugs Market Value (US$ Mn), By Mechanism of Action, 2020-2034
• Table 66. Russia Anti-obesity Drugs Market Value (US$ Mn), By Gut-Hormone Incretins, 2020-2034
• Table 67. Russia Anti-obesity Drugs Market Value (US$ Mn), By Route of Administration, 2020-2034
• Table 68. Russia Anti-obesity Drugs Market Value (US$ Mn), By Patient Type, 2020-2034
• Table 69. Russia Anti-obesity Drugs Market Value (US$ Mn), By Distribution Channel, 2020-2034
• Table 70. Netherland Anti-obesity Drugs Market Value (US$ Mn), By Drug Type, 2020-2034
• Table 71. Netherland Anti-obesity Drugs Market Value (US$ Mn), By Mechanism of Action, 2020-2034
• Table 72. Netherland Anti-obesity Drugs Market Value (US$ Mn), By Gut-Hormone Incretins, 2020-2034
• Table 73. Netherland Anti-obesity Drugs Market Value (US$ Mn), By Route of Administration, 2020-2034
• Table 74. Netherland Anti-obesity Drugs Market Value (US$ Mn), By Patient Type, 2020-2034
• Table 75. Netherland Anti-obesity Drugs Market Value (US$ Mn), By Distribution Channel, 2020-2034
• Table 76. Rest of Europe Anti-obesity Drugs Market Value (US$ Mn), By Drug Type, 2020-2034
• Table 77. Rest of Europe Anti-obesity Drugs Market Value (US$ Mn), By Mechanism of Action, 2020-2034
• Table 78. Rest of Europe Anti-obesity Drugs Market Value (US$ Mn), By Gut-Hormone Incretins, 2020-2034
• Table 79. Rest of Europe Anti-obesity Drugs Market Value (US$ Mn), By Route of Administration, 2020-2034
• Table 80. Rest of Europe Anti-obesity Drugs Market Value (US$ Mn), By Patient Type, 2020-2034
• Table 81. Rest of Europe Anti-obesity Drugs Market Value (US$ Mn), By Distribution Channel, 2020-2034
• Table 82. Asia Pacific Anti-obesity Drugs Market Value (US$ Mn), By Drug Type, 2020-2034
• Table 83. Asia Pacific Anti-obesity Drugs Market Value (US$ Mn), By Mechanism of Action, 2020-2034
• Table 84. Asia Pacific Anti-obesity Drugs Market Value (US$ Mn), By Gut-Hormone Incretins, 2020-2034
• Table 85. Asia Pacific Anti-obesity Drugs Market Value (US$ Mn), By Route of Administration, 2020-2034
• Table 86. Asia Pacific Anti-obesity Drugs Market Value (US$ Mn), By Patient Type, 2020-2034
• Table 87. Asia Pacific Anti-obesity Drugs Market Value (US$ Mn), By Distribution Channel, 2020-2034
• Table 88. Asia Pacific Anti-obesity Drugs Market Value (US$ Mn), By Country, 2020-2034
• Table 89. China Anti-obesity Drugs Market Value (US$ Mn), By Drug Type, 2020-2034
• Table 90. China Anti-obesity Drugs Market Value (US$ Mn), By Mechanism of Action, 2020-2034
• Table 91. China Anti-obesity Drugs Market Value (US$ Mn), By Gut-Hormone Incretins, 2020-2034
• Table 92. China Anti-obesity Drugs Market Value (US$ Mn), By Route of Administration, 2020-2034
• Table 93. China Anti-obesity Drugs Market Value (US$ Mn), By Patient Type, 2020-2034
• Table 94. China Anti-obesity Drugs Market Value (US$ Mn), By Distribution Channel, 2020-2034
• Table 95. India Anti-obesity Drugs Market Value (US$ Mn), By Drug Type, 2020-2034
• Table 96. India Anti-obesity Drugs Market Value (US$ Mn), By Mechanism of Action, 2020-2034
• Table 97. India Anti-obesity Drugs Market Value (US$ Mn), By Gut-Hormone Incretins, 2020-2034
• Table 98. India Anti-obesity Drugs Market Value (US$ Mn), By Route of Administration, 2020-2034
• Table 99. India Anti-obesity Drugs Market Value (US$ Mn), By Patient Type, 2020-2034
• Table 100. India Anti-obesity Drugs Market Value (US$ Mn), By Distribution Channel, 2020-2034
• Table 101. Japan Anti-obesity Drugs Market Value (US$ Mn), By Drug Type, 2020-2034
• Table 102. Japan Anti-obesity Drugs Market Value (US$ Mn), By Mechanism of Action, 2020-2034
• Table 103. Japan Anti-obesity Drugs Market Value (US$ Mn), By Gut-Hormone Incretins, 2020-2034
• Table 104. Japan Anti-obesity Drugs Market Value (US$ Mn), By Route of Administration, 2020-2034
• Table 105. Japan Anti-obesity Drugs Market Value (US$ Mn), By Patient Type, 2020-2034
• Table 106. Japan Anti-obesity Drugs Market Value (US$ Mn), By Distribution Channel, 2020-2034
• Table 107. South Korea Anti-obesity Drugs Market Value (US$ Mn), By Drug Type, 2020-2034
• Table 108. South Korea Anti-obesity Drugs Market Value (US$ Mn), By Mechanism of Action, 2020-2034
• Table 109. South Korea Anti-obesity Drugs Market Value (US$ Mn), By Gut-Hormone Incretins, 2020-2034
• Table 110. South Korea Anti-obesity Drugs Market Value (US$ Mn), By Route of Administration, 2020-2034
• Table 111. South Korea Anti-obesity Drugs Market Value (US$ Mn), By Patient Type, 2020-2034
• Table 112. South Korea Anti-obesity Drugs Market Value (US$ Mn), By Distribution Channel, 2020-2034
• Table 113. Australia Anti-obesity Drugs Market Value (US$ Mn), By Drug Type, 2020-2034
• Table 114. Australia Anti-obesity Drugs Market Value (US$ Mn), By Mechanism of Action, 2020-2034
• Table 115. Australia Anti-obesity Drugs Market Value (US$ Mn), By Gut-Hormone Incretins, 2020-2034
• Table 116. Australia Anti-obesity Drugs Market Value (US$ Mn), By Route of Administration, 2020-2034
• Table 117. Australia Anti-obesity Drugs Market Value (US$ Mn), By Patient Type, 2020-2034
• Table 118. Australia Anti-obesity Drugs Market Value (US$ Mn), By Distribution Channel, 2020-2034
• Table 119. New Zealand Anti-obesity Drugs Market Value (US$ Mn), By Drug Type, 2020-2034
• Table 120. New Zealand Anti-obesity Drugs Market Value (US$ Mn), By Mechanism of Action, 2020-2034
• Table 121. New Zealand Anti-obesity Drugs Market Value (US$ Mn), By Gut-Hormone Incretins, 2020-2034
• Table 122. New Zealand Anti-obesity Drugs Market Value (US$ Mn), By Route of Administration, 2020-2034
• Table 123. New Zealand Anti-obesity Drugs Market Value (US$ Mn), By Patient Type, 2020-2034
• Table 124. New Zealand Anti-obesity Drugs Market Value (US$ Mn), By Distribution Channel, 2020-2034
• Table 125. Singapore Anti-obesity Drugs Market Value (US$ Mn), By Drug Type, 2020-2034
• Table 126. Singapore Anti-obesity Drugs Market Value (US$ Mn), By Mechanism of Action, 2020-2034
• Table 127. Singapore Anti-obesity Drugs Market Value (US$ Mn), By Gut-Hormone Incretins, 2020-2034
• Table 128. Singapore Anti-obesity Drugs Market Value (US$ Mn), By Route of Administration, 2020-2034
• Table 129. Singapore Anti-obesity Drugs Market Value (US$ Mn), By Patient Type, 2020-2034
• Table 130. Singapore Anti-obesity Drugs Market Value (US$ Mn), By Distribution Channel, 2020-2034
• Table 131. Thailand Anti-obesity Drugs Market Value (US$ Mn), By Drug Type, 2020-2034
• Table 132. Thailand Anti-obesity Drugs Market Value (US$ Mn), By Mechanism of Action, 2020-2034
• Table 133. Thailand Anti-obesity Drugs Market Value (US$ Mn), By Gut-Hormone Incretins, 2020-2034
• Table 134. Thailand Anti-obesity Drugs Market Value (US$ Mn), By Route of Administration, 2020-2034
• Table 135. Thailand Anti-obesity Drugs Market Value (US$ Mn), By Patient Type, 2020-2034
• Table 136. Thailand Anti-obesity Drugs Market Value (US$ Mn), By Distribution Channel, 2020-2034
• Table 137. Vietnam Anti-obesity Drugs Market Value (US$ Mn), By Drug Type, 2020-2034
• Table 138. Vietnam Anti-obesity Drugs Market Value (US$ Mn), By Mechanism of Action, 2020-2034
• Table 139. Vietnam Anti-obesity Drugs Market Value (US$ Mn), By Gut-Hormone Incretins, 2020-2034
• Table 140. Vietnam Anti-obesity Drugs Market Value (US$ Mn), By Route of Administration, 2020-2034
• Table 141. Vietnam Anti-obesity Drugs Market Value (US$ Mn), By Patient Type, 2020-2034
• Table 142. Vietnam Anti-obesity Drugs Market Value (US$ Mn), By Distribution Channel, 2020-2034
• Table 143. Rest of Asia Pacific Anti-obesity Drugs Market Value (US$ Mn), By Drug Type, 2020-2034
• Table 144. Rest of Asia Pacific Anti-obesity Drugs Market Value (US$ Mn), By Mechanism of Action, 2020-2034
• Table 145. Rest of Asia Pacific Anti-obesity Drugs Market Value (US$ Mn), By Gut-Hormone Incretins, 2020-2034
• Table 146. Rest of Asia Pacific Anti-obesity Drugs Market Value (US$ Mn), By Route of Administration, 2020-2034
• Table 147. Rest of Asia Pacific Anti-obesity Drugs Market Value (US$ Mn), By Patient Type, 2020-2034
• Table 148. Rest of Asia Pacific Anti-obesity Drugs Market Value (US$ Mn), By Distribution Channel, 2020-2034
• Table 149. Latin America Anti-obesity Drugs Market Value (US$ Mn), By Drug Type, 2020-2034
• Table 150. Latin America Anti-obesity Drugs Market Value (US$ Mn), By Mechanism of Action, 2020-2034
• Table 151. Latin America Anti-obesity Drugs Market Value (US$ Mn), By Gut-Hormone Incretins, 2020-2034
• Table 152. Latin America Anti-obesity Drugs Market Value (US$ Mn), By Route of Administration, 2020-2034
• Table 153. Latin America Anti-obesity Drugs Market Value (US$ Mn), By Patient Type, 2020-2034
• Table 154. Latin America Anti-obesity Drugs Market Value (US$ Mn), By Distribution Channel, 2020-2034
• Table 155. Latin America Anti-obesity Drugs Market Value (US$ Mn), By Country, 2020-2034
• Table 156. Brazil Anti-obesity Drugs Market Value (US$ Mn), By Drug Type, 2020-2034
• Table 157. Brazil Anti-obesity Drugs Market Value (US$ Mn), By Mechanism of Action, 2020-2034
• Table 158. Brazil Anti-obesity Drugs Market Value (US$ Mn), By Gut-Hormone Incretins, 2020-2034
• Table 159. Brazil Anti-obesity Drugs Market Value (US$ Mn), By Route of Administration, 2020-2034
• Table 160. Brazil Anti-obesity Drugs Market Value (US$ Mn), By Patient Type, 2020-2034
• Table 161. Brazil Anti-obesity Drugs Market Value (US$ Mn), By Distribution Channel, 2020-2034
• Table 162. Mexico Anti-obesity Drugs Market Value (US$ Mn), By Drug Type, 2020-2034
• Table 163. Mexico Anti-obesity Drugs Market Value (US$ Mn), By Mechanism of Action, 2020-2034
• Table 164. Mexico Anti-obesity Drugs Market Value (US$ Mn), By Gut-Hormone Incretins, 2020-2034
• Table 165. Mexico Anti-obesity Drugs Market Value (US$ Mn), By Route of Administration, 2020-2034
• Table 166. Mexico Anti-obesity Drugs Market Value (US$ Mn), By Patient Type, 2020-2034
• Table 167. Mexico Anti-obesity Drugs Market Value (US$ Mn), By Distribution Channel, 2020-2034
• Table 168. Rest of Latin America Anti-obesity Drugs Market Value (US$ Mn), By Drug Type, 2020-2034
• Table 169. Rest of Latin America Anti-obesity Drugs Market Value (US$ Mn), By Mechanism of Action, 2020-2034
• Table 170. Rest of Latin America Anti-obesity Drugs Market Value (US$ Mn), By Gut-Hormone Incretins, 2020-2034
• Table 171. Rest of Latin America Anti-obesity Drugs Market Value (US$ Mn), By Route of Administration, 2020-2034
• Table 172. Rest of Latin America Anti-obesity Drugs Market Value (US$ Mn), By Patient Type, 2020-2034
• Table 173. Rest of Latin America Anti-obesity Drugs Market Value (US$ Mn), By Distribution Channel, 2020-2034
• Table 174. Middle East & Africa Anti-obesity Drugs Market Value (US$ Mn), By Drug Type, 2020-2034
• Table 175. Middle East & Africa Anti-obesity Drugs Market Value (US$ Mn), By Mechanism of Action, 2020-2034
• Table 176. Middle East & Africa Anti-obesity Drugs Market Value (US$ Mn), By Gut-Hormone Incretins, 2020-2034
• Table 177. Middle East & Africa Anti-obesity Drugs Market Value (US$ Mn), By Route of Administration, 2020-2034
• Table 178. Middle East & Africa Anti-obesity Drugs Market Value (US$ Mn), By Patient Type, 2020-2034
• Table 179. Middle East & Africa Anti-obesity Drugs Market Value (US$ Mn), By Distribution Channel, 2020-2034
• Table 180. Middle East & Africa Anti-obesity Drugs Market Value (US$ Mn), By Country, 2020-2034
• Table 181. South Africa Anti-obesity Drugs Market Value (US$ Mn), By Drug Type, 2020-2034
• Table 182. South Africa Anti-obesity Drugs Market Value (US$ Mn), By Mechanism of Action, 2020-2034
• Table 183. South Africa Anti-obesity Drugs Market Value (US$ Mn), By Gut-Hormone Incretins, 2020-2034
• Table 184. South Africa Anti-obesity Drugs Market Value (US$ Mn), By Route of Administration, 2020-2034
• Table 185. South Africa Anti-obesity Drugs Market Value (US$ Mn), By Patient Type, 2020-2034
• Table 186. South Africa Anti-obesity Drugs Market Value (US$ Mn), By Distribution Channel, 2020-2034
• Table 187. Saudi Arabia Anti-obesity Drugs Market Value (US$ Mn), By Drug Type, 2020-2034
• Table 188. Saudi Arabia Anti-obesity Drugs Market Value (US$ Mn), By Mechanism of Action, 2020-2034
• Table 189. Saudi Arabia Anti-obesity Drugs Market Value (US$ Mn), By Gut-Hormone Incretins, 2020-2034
• Table 190. Saudi Arabia Anti-obesity Drugs Market Value (US$ Mn), By Route of Administration, 2020-2034
• Table 191. Saudi Arabia Anti-obesity Drugs Market Value (US$ Mn), By Patient Type, 2020-2034
• Table 192. Saudi Arabia Anti-obesity Drugs Market Value (US$ Mn), By Distribution Channel, 2020-2034
• Table 193. UAE Anti-obesity Drugs Market Value (US$ Mn), By Drug Type, 2020-2034
• Table 194. UAE Anti-obesity Drugs Market Value (US$ Mn), By Mechanism of Action, 2020-2034
• Table 195. UAE Anti-obesity Drugs Market Value (US$ Mn), By Gut-Hormone Incretins, 2020-2034
• Table 196. UAE Anti-obesity Drugs Market Value (US$ Mn), By Route of Administration, 2020-2034
• Table 197. UAE Anti-obesity Drugs Market Value (US$ Mn), By Patient Type, 2020-2034
• Table 198. UAE Anti-obesity Drugs Market Value (US$ Mn), By Distribution Channel, 2020-2034
• Table 199. Rest of Middle East & Africa Anti-obesity Drugs Market Value (US$ Mn), By Drug Type, 2020-2034
• Table 200. Rest of Middle East & Africa Anti-obesity Drugs Market Value (US$ Mn), By Mechanism of Action, 2020-2034
• Table 201. Rest of Middle East & Africa Anti-obesity Drugs Market Value (US$ Mn), By Gut-Hormone Incretins, 2020-2034
• Table 202. Rest of Middle East & Africa Anti-obesity Drugs Market Value (US$ Mn), By Route of Administration, 2020-2034
• Table 203. Rest of Middle East & Africa Anti-obesity Drugs Market Value (US$ Mn), By Patient Type, 2020-2034
• Table 204. Rest of Middle East & Africa Anti-obesity Drugs Market Value (US$ Mn), By Distribution Channel, 2020-2034

List of Figures

• Figure 1. Global Anti-obesity Drugs Market Snapshot: Market Value (US$ Mn), 2020-2034
• Figure 2. Opportunity Map
• Figure 3. Opportunity Orbit
• Figure 4. Regional Market Share and BPS Analysis in Anti-obesity Drugs Market
• Figure 5. Global Anti-obesity Drugs Market Analysis, By Drug Type, 2020, 2024 and 2034
• Figure 6. Global Anti-obesity Drugs Market Attractiveness Analysis, By Drug Type
• Figure 7. Global Anti-obesity Drugs Market Analysis, By Mechanism of Action, 2020, 2024 and 2034
• Figure 8. Global Anti-obesity Drugs Market Attractiveness Analysis, By Mechanism of Action
• Figure 9. Global Anti-obesity Drugs Market Analysis, By Route of Administration, 2020, 2024 and 2034
• Figure 10. Global Anti-obesity Drugs Market Attractiveness Analysis, By Route of Administration
• Figure 11. Global Anti-obesity Drugs Market Analysis, By Patient Type, 2020, 2024 and 2034
• Figure 12. Global Anti-obesity Drugs Market Attractiveness Analysis, By Patient Type
• Figure 13. Global Anti-obesity Drugs Market Analysis, By Distribution Channel, 2020, 2024 and 2034
• Figure 14. Global Anti-obesity Drugs Market Attractiveness Analysis, By Distribution Channel
• Figure 15. Global Anti-obesity Drugs Market Analysis, By Region, 2020, 2024 and 2034
• Figure 16. Global Anti-obesity Drugs Market Attractiveness Analysis, By Region
• Figure 17. North America Anti-obesity Drugs Market Analysis, By Drug Type, 2020, 2024 and 2034
• Figure 18. North America Anti-obesity Drugs Market Attractiveness Analysis, By Drug Type
• Figure 19. North America Anti-obesity Drugs Market (US$ Mn), by Prescription Drugs, 2020-2034
• Figure 20. North America Anti-obesity Drugs Market (US$ Mn), by OTC Drugs, 2020-2034
• Figure 21. North America Anti-obesity Drugs Market Analysis, By Mechanism of Action, 2020, 2024 and 2034
• Figure 22. North America Anti-obesity Drugs Market Attractiveness Analysis, By Mechanism of Action
• Figure 23. North America Anti-obesity Drugs Market (US$ Mn), by Centrally Acting Drugs, 2020-2034
• Figure 24. North America Anti-obesity Drugs Market (US$ Mn), by Peripherally Acting Drugs, 2020-2034
• Figure 25. North America Anti-obesity Drugs Market (US$ Mn), by Gut-Hormone Incretins, 2020-2034
• Figure 26. North America Anti-obesity Drugs Market Analysis, By Route of Administration, 2020, 2024 and 2034
• Figure 27. North America Anti-obesity Drugs Market Attractiveness Analysis, By Route of Administration
• Figure 28. North America Anti-obesity Drugs Market (US$ Mn), by Oral, 2020-2034
• Figure 29. North America Anti-obesity Drugs Market (US$ Mn), by Injectable, 2020-2034
• Figure 30. North America Anti-obesity Drugs Market Analysis, By Patient Type, 2020, 2024 and 2034
• Figure 31. North America Anti-obesity Drugs Market Attractiveness Analysis, By Patient Type
• Figure 32. North America Anti-obesity Drugs Market (US$ Mn), by Adults, 2020-2034
• Figure 33. North America Anti-obesity Drugs Market (US$ Mn), by Pediatrics, 2020-2034
• Figure 34. North America Anti-obesity Drugs Market Analysis, By Distribution Channel, 2020, 2024 and 2034
• Figure 35. North America Anti-obesity Drugs Market Attractiveness Analysis, By Distribution Channel
• Figure 36. North America Anti-obesity Drugs Market (US$ Mn), by Hospital Pharmacies, 2020-2034
• Figure 37. North America Anti-obesity Drugs Market (US$ Mn), by Retail Pharmacies, 2020-2034
• Figure 38. North America Anti-obesity Drugs Market (US$ Mn), by Online Pharmacies, 2020-2034
• Figure 39. North America Anti-obesity Drugs Market Analysis, By Country, 2020, 2024 and 2034
• Figure 40. North America Anti-obesity Drugs Market Attractiveness Analysis, By Country
• Figure 41. Europe Anti-obesity Drugs Market Analysis, By Drug Type, 2020, 2024 and 2034
• Figure 42. Europe Anti-obesity Drugs Market Attractiveness Analysis, By Drug Type
• Figure 43. Europe Anti-obesity Drugs Market (US$ Mn), by Prescription Drugs, 2020-2034
• Figure 44. Europe Anti-obesity Drugs Market (US$ Mn), by OTC Drugs, 2020-2034
• Figure 45. Europe Anti-obesity Drugs Market Analysis, By Mechanism of Action, 2020, 2024 and 2034
• Figure 46. Europe Anti-obesity Drugs Market Attractiveness Analysis, By Mechanism of Action
• Figure 47. Europe Anti-obesity Drugs Market (US$ Mn), by Centrally Acting Drugs, 2020-2034
• Figure 48. Europe Anti-obesity Drugs Market (US$ Mn), by Peripherally Acting Drugs, 2020-2034
• Figure 49. Europe Anti-obesity Drugs Market (US$ Mn), by Gut-Hormone Incretins, 2020-2034
• Figure 50. Europe Anti-obesity Drugs Market Analysis, By Route of Administration, 2020, 2024 and 2034
• Figure 51. Europe Anti-obesity Drugs Market Attractiveness Analysis, By Route of Administration
• Figure 52. Europe Anti-obesity Drugs Market (US$ Mn), by Oral, 2020-2034
• Figure 53. Europe Anti-obesity Drugs Market (US$ Mn), by Injectable, 2020-2034
• Figure 54. Europe Anti-obesity Drugs Market Analysis, By Patient Type, 2020, 2024 and 2034
• Figure 55. Europe Anti-obesity Drugs Market Attractiveness Analysis, By Patient Type
• Figure 56. Europe Anti-obesity Drugs Market (US$ Mn), by Adults, 2020-2034
• Figure 57. Europe Anti-obesity Drugs Market (US$ Mn), by Pediatrics, 2020-2034
• Figure 58. Europe Anti-obesity Drugs Market Analysis, By Distribution Channel, 2020, 2024 and 2034
• Figure 59. Europe Anti-obesity Drugs Market Attractiveness Analysis, By Distribution Channel
• Figure 60. Europe Anti-obesity Drugs Market (US$ Mn), by Hospital Pharmacies, 2020-2034
• Figure 61. Europe Anti-obesity Drugs Market (US$ Mn), by Retail Pharmacies, 2020-2034
• Figure 62. Europe Anti-obesity Drugs Market (US$ Mn), by Online Pharmacies, 2020-2034
• Figure 63. Europe Anti-obesity Drugs Market Analysis, By Country, 2020, 2024 and 2034
• Figure 64. Europe Anti-obesity Drugs Market Attractiveness Analysis, By Country
• Figure 65. Asia Pacific Anti-obesity Drugs Market Analysis, By Drug Type, 2020, 2024 and 2034
• Figure 66. Asia Pacific Anti-obesity Drugs Market Attractiveness Analysis, By Drug Type
• Figure 67. Asia Pacific Anti-obesity Drugs Market (US$ Mn), by Prescription Drugs, 2020-2034
• Figure 68. Asia Pacific Anti-obesity Drugs Market (US$ Mn), by OTC Drugs, 2020-2034
• Figure 69. Asia Pacific Anti-obesity Drugs Market Analysis, By Mechanism of Action, 2020, 2024 and 2034
• Figure 70. Asia Pacific Anti-obesity Drugs Market Attractiveness Analysis, By Mechanism of Action
• Figure 71. Asia Pacific Anti-obesity Drugs Market (US$ Mn), by Centrally Acting Drugs, 2020-2034
• Figure 72. Asia Pacific Anti-obesity Drugs Market (US$ Mn), by Peripherally Acting Drugs, 2020-2034
• Figure 73. Asia Pacific Anti-obesity Drugs Market (US$ Mn), by Gut-Hormone Incretins, 2020-2034
• Figure 74. Asia Pacific Anti-obesity Drugs Market Analysis, By Route of Administration, 2020, 2024 and 2034
• Figure 75. Asia Pacific Anti-obesity Drugs Market Attractiveness Analysis, By Route of Administration
• Figure 76. Asia Pacific Anti-obesity Drugs Market (US$ Mn), by Oral, 2020-2034
• Figure 77. Asia Pacific Anti-obesity Drugs Market (US$ Mn), by Injectable, 2020-2034
• Figure 78. Asia Pacific Anti-obesity Drugs Market Analysis, By Patient Type, 2020, 2024 and 2034
• Figure 79. Asia Pacific Anti-obesity Drugs Market Attractiveness Analysis, By Patient Type
• Figure 80. Asia Pacific Anti-obesity Drugs Market (US$ Mn), by Adults, 2020-2034
• Figure 81. Asia Pacific Anti-obesity Drugs Market (US$ Mn), by Pediatrics, 2020-2034
• Figure 82. Asia Pacific Anti-obesity Drugs Market Analysis, By Distribution Channel, 2020, 2024 and 2034
• Figure 83. Asia Pacific Anti-obesity Drugs Market Attractiveness Analysis, By Distribution Channel
• Figure 84. Asia Pacific Anti-obesity Drugs Market (US$ Mn), by Hospital Pharmacies, 2020-2034
• Figure 85. Asia Pacific Anti-obesity Drugs Market (US$ Mn), by Retail Pharmacies, 2020-2034
• Figure 86. Asia Pacific Anti-obesity Drugs Market (US$ Mn), by Online Pharmacies, 2020-2034
• Figure 87. Asia Pacific Anti-obesity Drugs Market Analysis, By Country, 2020, 2024 and 2034
• Figure 88. Asia Pacific Anti-obesity Drugs Market Attractiveness Analysis, By Country
• Figure 89. Latin America Anti-obesity Drugs Market Analysis, By Drug Type, 2020, 2024 and 2034
• Figure 90. Latin America Anti-obesity Drugs Market Attractiveness Analysis, By Drug Type
• Figure 91. Latin America Anti-obesity Drugs Market (US$ Mn), by Prescription Drugs, 2020-2034
• Figure 92. Latin America Anti-obesity Drugs Market (US$ Mn), by OTC Drugs, 2020-2034
• Figure 93. Latin America Anti-obesity Drugs Market Analysis, By Mechanism of Action, 2020, 2024 and 2034
• Figure 94. Latin America Anti-obesity Drugs Market Attractiveness Analysis, By Mechanism of Action
• Figure 95. Latin America Anti-obesity Drugs Market (US$ Mn), by Centrally Acting Drugs, 2020-2034
• Figure 96. Latin America Anti-obesity Drugs Market (US$ Mn), by Peripherally Acting Drugs, 2020-2034
• Figure 97. Latin America Anti-obesity Drugs Market (US$ Mn), by Gut-Hormone Incretins, 2020-2034
• Figure 98. Latin America Anti-obesity Drugs Market Analysis, By Route of Administration, 2020, 2024 and 2034
• Figure 99. Latin America Anti-obesity Drugs Market Attractiveness Analysis, By Route of Administration
• Figure 100. Latin America Anti-obesity Drugs Market (US$ Mn), by Oral, 2020-2034
• Figure 101. Latin America Anti-obesity Drugs Market (US$ Mn), by Injectable, 2020-2034
• Figure 102. Latin America Anti-obesity Drugs Market Analysis, By Patient Type, 2020, 2024 and 2034
• Figure 103. Latin America Anti-obesity Drugs Market Attractiveness Analysis, By Patient Type
• Figure 104. Latin America Anti-obesity Drugs Market (US$ Mn), by Adults, 2020-2034
• Figure 105. Latin America Anti-obesity Drugs Market (US$ Mn), by Pediatrics, 2020-2034
• Figure 106. Latin America Anti-obesity Drugs Market Analysis, By Distribution Channel, 2020, 2024 and 2034
• Figure 107. Latin America Anti-obesity Drugs Market Attractiveness Analysis, By Distribution Channel
• Figure 108. Latin America Anti-obesity Drugs Market (US$ Mn), by Hospital Pharmacies, 2020-2034
• Figure 109. Latin America Anti-obesity Drugs Market (US$ Mn), by Retail Pharmacies, 2020-2034
• Figure 110. Latin America Anti-obesity Drugs Market (US$ Mn), by Online Pharmacies, 2020-2034
• Figure 111. Latin America Anti-obesity Drugs Market Analysis, By Country, 2020, 2024 and 2034
• Figure 112. Latin America Anti-obesity Drugs Market Attractiveness Analysis, By Country
• Figure 113. Middle East & Africa Anti-obesity Drugs Market Analysis, By Drug Type, 2020, 2024 and 2034
• Figure 114. Middle East & Africa Anti-obesity Drugs Market Attractiveness Analysis, By Drug Type
• Figure 115. Middle East & Africa Anti-obesity Drugs Market (US$ Mn), by Prescription Drugs, 2020-2034
• Figure 116. Middle East & Africa Anti-obesity Drugs Market (US$ Mn), by OTC Drugs, 2020-2034
• Figure 117. Middle East & Africa Anti-obesity Drugs Market Analysis, By Mechanism of Action, 2020, 2024 and 2034
• Figure 118. Middle East & Africa Anti-obesity Drugs Market Attractiveness Analysis, By Mechanism of Action
• Figure 119. Middle East & Africa Anti-obesity Drugs Market (US$ Mn), by Centrally Acting Drugs, 2020-2034
• Figure 120. Middle East & Africa Anti-obesity Drugs Market (US$ Mn), by Peripherally Acting Drugs, 2020-2034
• Figure 121. Middle East & Africa Anti-obesity Drugs Market (US$ Mn), by Gut-Hormone Incretins, 2020-2034
• Figure 122. Middle East & Africa Anti-obesity Drugs Market Analysis, By Route of Administration, 2020, 2024 and 2034
• Figure 123. Middle East & Africa Anti-obesity Drugs Market Attractiveness Analysis, By Route of Administration
• Figure 124. Middle East & Africa Anti-obesity Drugs Market (US$ Mn), by Oral, 2020-2034
• Figure 125. Middle East & Africa Anti-obesity Drugs Market (US$ Mn), by Injectable, 2020-2034
• Figure 126. Middle East & Africa Anti-obesity Drugs Market Analysis, By Patient Type, 2020, 2024 and 2034
• Figure 127. Middle East & Africa Anti-obesity Drugs Market Attractiveness Analysis, By Patient Type
• Figure 128. Middle East & Africa Anti-obesity Drugs Market (US$ Mn), by Adults, 2020-2034
• Figure 129. Middle East & Africa Anti-obesity Drugs Market (US$ Mn), by Pediatrics, 2020-2034
• Figure 130. Middle East & Africa Anti-obesity Drugs Market Analysis, By Distribution Channel, 2020, 2024 and 2034
• Figure 131. Middle East & Africa Anti-obesity Drugs Market Attractiveness Analysis, By Distribution Channel
• Figure 132. Middle East & Africa Anti-obesity Drugs Market (US$ Mn), by Hospital Pharmacies, 2020-2034
• Figure 133. Middle East & Africa Anti-obesity Drugs Market (US$ Mn), by Retail Pharmacies, 2020-2034
• Figure 134. Middle East & Africa Anti-obesity Drugs Market (US$ Mn), by Online Pharmacies, 2020-2034
• Figure 135. Middle East & Africa Anti-obesity Drugs Market Analysis, By Country, 2020, 2024 and 2034
• Figure 136. Middle East & Africa Anti-obesity Drugs Market Attractiveness Analysis, By Country